Phase3 Studie RTB101 floppt
ir.restorbio.com/news-releases/...r-1-trial-rtb101-clinically
Zahlen für Q3/19
- keine Umsätze
- Verlust 24 Mio. $
- Cash 117 Mio. $
- MK 49 Mio. $
ir.restorbio.com/news-releases/...-2019-financial-results-and
|
Phase3 Studie RTB101 floppt
ir.restorbio.com/news-releases/...r-1-trial-rtb101-clinically
Zahlen für Q3/19
ir.restorbio.com/news-releases/...-2019-financial-results-and
Merger mit Adicet Bio
endpts.com/...es-with-t-cell-biotech-after-big-phiii-failure/
Zahlen für Q2/2021
The Company expects that current cash, cash equivalents and marketable securities as of June 30, 2021 will be sufficient to fund its operating expenses through the beginning of the second half of 2023.
- On track to report top-line interim data from ADI-001 Phase 1 study in Non-Hodgkin's Lymphoma (NHL) by the end of 2021
investor.adicetbio.com/news-releases/...financial-results-and
88 Mio. $ Offering
investor.adicetbio.com/news-releases/...offering-common-stock
Gutes Timing und auch die Konditionen können sich sehen lassen, wenn man sich den Chart der letzten Monate so anschaut.
Regeneron übt Lizenz-Option für ADI-002 aus
ACET bekommt dafür 20 Mio. $.
www.sec.gov/ix?doc=/Archives/edgar/data/.../acet-20220128.htm
FDA Fast Track Status für ADI-001
investor.adicetbio.com/news-releases/...nation-lead-candidate
Zahlen für Q4/21
- to fund its operating expenses at least into the second half of 2024
investor.adicetbio.com/news-releases/...l-year-2021-financial
Zahlen für Q3/22
- Cash runway into first half of 2025
investor.adicetbio.com/news-releases/...-results-and-provides
Zahlen für Q4/22
- Announced interim safety and efficacy data for ADI-001 in ongoing Phase 1 study for the potential treatment of relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL); Next data update expected in Q2 2023
investor.adicetbio.com/news-releases/...l-year-2022-financial
Zahlen für Q1/23
investor.adicetbio.com/news-releases/...-results-and-provides
Downgrade von JPM auf neutral (wegen "fehlender kurzfristiger Katalysatoren")
Phase-1-Studie ADI-001 (NHL)
investor.adicetbio.com/news-releases/...i-001-phase-1-trial-0
|
Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
41 | TORC 1,40$ (-82%) | Vassago | Balu4u | 15.02.24 06:36 |